Table of Content



Chapter 1 Methodology and Scope
1.1 Research Methodology
1.1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.3.1 CAGR Calculation
1.4 Region Based Segment Share Calculation
1.5 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 U.S. Cannabinoids Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Penetration & Growth Prospects Mapping
3.3 U.S. Cannabinoids Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Growing number of new entrants in the market leading to expansion in product availability
3.3.1.2 Increasing number of consumers opting for isolated cannabinoid products
3.3.1.3 Growing number of clinical studies on the use of cannabinoids for specific applications
3.3.1.4 Rising awareness pertaining to cannabinoid products and their use in health and wellness
3.3.2 Market Restraint Analysis
3.3.2.1 High price of cannabinoids-based products
3.3.2.2 Expensive extraction processes for cannabinoids
3.3.2.3 Absence of definite regulatory framework for minor cannabinoids
3.4 U.S. Cannabinoids Market Analysis Tools
3.4.1 U.S. Cannabinoids Market - PESTLE Analysis
3.4.2 U.S. Cannabinoids Market - Porter’s Analysis
3.5 Supply Chain Analysis
3.5.1 Supply Chain Analysis - CBD Consumer Health Product
3.5.1.1 Profit Margin Estimation
3.6 Opportunity Analysis
3.7 Regulatory Scenario
3.8 Product Adoption Pattern Analysis
3.8.1 Cannabidiol (CBD)
3.8.2 Tetrahydrocannabinol (THC)
3.8.3 Cannabinol (CBN)
3.8.4 Cannabidiolic Acid (CBDA)
3.8.5 Others
3.8.5.1 Cannabigerol (CBG)
3.8.5.2 Cannabichromene (CBC)
3.9 Pricing Analysis, Product Type, 2019-2027
Chapter 4 U.S Cannabinoids Market: Product Estimates & Trend Analysis
4.1 U.S. Cannabinoids Market: Product Movement Analysis
4.2 Market Revenue Size and Forecasts and Trend Analysis 2016-2027 for the following product types:
4.2.1 Cannabidiol (CBD)
4.2.1.1 CBD Market Estimates and Forecasts, 2016 - 2027 (USD Million)
4.2.2 Tetrahydrocannabinol (THC)
4.2.2.1 THC Market Estimates and Forecasts, 2016 - 2027 (USD Million)
4.2.3 Cannabinol (CBN)
4.2.3.1 CBN Market Estimates and Forecasts, 2016 - 2027 (USD Million)
4.2.4 Cannabidiolic Acid (CBDA)
4.2.4.1 CBDa Market Estimates and Forecasts, 2016 - 2027 (USD Million)
4.2.5 Other Cannabinoids (CBG AND CBC)
4.2.5.1 Other Cannabinoids (CBG and CBC) Market Estimates and Forecasts, 2016 - 2027 (USD Million)
Chapter 5 Competitive Landscape
5.1 Company Profiles
5.1.1 Mile High Labs International
5.1.1.1 Company overview
5.1.1.2 Financial performance
5.1.1.3 Product benchmarking
5.1.1.4 Strategic initiatives
5.1.2 Global Cannabinoids
5.1.2.1 Company overview
5.1.2.2 Financial performance
5.1.2.3 Product benchmarking
5.1.2.4 Strategic initiatives
5.1.3 Gencanna
5.1.3.1 Company overview
5.1.3.2 Financial performance
5.1.3.3 Product benchmarking
5.1.3.4 Strategic initiatives
5.1.4 CBD Inc Group
5.1.4.1 Company overview
5.1.4.2 Product benchmarking
5.1.5 SPARKCBD
5.1.5.1 Company overview
5.1.5.2 Product benchmarking
5.1.6 Rhizo Sciences
5.1.6.1 Company overview
5.1.6.2 Financial performance
5.1.6.3 Product benchmarking
5.1.6.4 Strategic initiatives
5.1.7 Maricann, Inc.
5.1.7.1 Company overview
5.1.7.2 Product benchmarking



List of Tables



Table 1 Partial list of secondary sources
Table 2 Average Selling price of cannabinoids in the U.S., by product, 2019 - 2027 (USD/mg)